| The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy. | |
| | |
MedLine Citation:
|
PMID: 20497250 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
OBJECTIVE: The aim of the study was to compare the metabolic and morphological effects of enfuvirtide plus an optimized background (OB) regimen vs. OB alone (control group) in treatment-experienced patients in the T-20 vs. Optimized Regimen Only (TORO) studies. METHODS: Body composition and metabolic changes were investigated in patients over 48 weeks, based on fasting chemistries, body weight, and other anthropometric measurements. Dual-energy X-ray absorptiometry (DEXA) and computed tomography (CT) scans were performed in a patient subgroup (n=155) at baseline and at weeks 24 and 48. RESULTS: At week 48, mean changes from baseline were similar between treatment groups for glucose, insulin, C-peptide, total cholesterol, low-density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglyceride levels. The enfuvirtide group experienced a significant increase in body weight [mean change from baseline +0.99 kg; 95% confidence interval (CI) +0.54, +1.44] and, in those who had body scans, there was a significant increase in truncal fat (by DEXA: median change +419.4 g; 95% CI+71.3, +767.5) and total fat [visceral adipose tissue (VAT)+subcutaneous adipose tissue (SAT) by single-slice abdominal CT scan: median change +25.5 cm(2) ; 95% CI+8.9, +42.0] over 48 weeks; significant increases in these parameters were not seen in the control group. There was no significant change in truncal:peripheral fat ratio in either the enfuvirtide or the control group. CONCLUSION: The addition of enfuvirtide to an OB regimen does not appear to have unfavourable effects on fat distribution or metabolic parameters. |
| | |
Authors:
|
D A Cooper; D V Cordery; P Reiss; K Henry; M Nelson; M O'Hearn; J Reynes; K Arastéh; J Chung; L Rowell; D Guimaraes; A Bertasso; |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: HIV medicine Volume: 12 ISSN: 1468-1293 ISO Abbreviation: HIV Med. Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-06 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897392 Medline TA: HIV Med Country: England |
Other Details:
|
Languages: eng Pagination: 31-9 Citation Subset: IM |
Copyright Information:
|
© 2010 British HIV Association. |
Affiliation:
|
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia. dcooper@nchecr.unsw.edu.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Investigator | |
Investigator/Affiliation:
|
Belinda Atkins / ; Silvia Bader-Weder / ; Laurence Bourdeau / ; Neil E Buss / ; Bonaventura Clotet / ; Calvin Cohen / ; Jean-Francois Delfraissy / ; Ralph DeMasi / ; Lucille Donatacci / ; Claude Drobnes / ; Joseph J Eron / ; Fiona Hughes / ; Christine Katlama / ; Tosca Kinchelow / ; Daniel Kuritzkes / ; Emily Labriola-Tomkins / ; Jacob Lalezari / ; Joep Lange / ; Adriano Lazzarin / ; Julio Montaner / ; Christopher Natale / ; Peter Piliero / ; Miklos P Salgo / ; Anna Shikhman / ; Lynn Smiley / ; Hans-Jurgen Stellbrink / ; Benoit Trottier / ; Adeline Valentine / ; Sharon Walmsley / ; Cynthia Wat / ; Martin Wilkinson / |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measuremen...
Next Document: Assessment of factors influencing health-related quality of life in HIV-infected patients.